[Investigation on radiosensitizing and tumor inhibiting actions of the antioxidant MTDQ (6,6'-methylen-bis/2,2,4-trimethyl-1-1,2-dihydroquinolin) (author's transl)].
Unlike the hitherto known antioxidants, MTDQ is not a radiation protective-but a radiation sensitizing agent. According to autoradiographic findings accumulation of 14C-labelled MTDQ occurs in tumor tissue. The compound was found to be suitable in the combined treatment (MTDQ and 300 R x-ray therapy). In these instances tumor weight of solid Ehrlich- and Yoshida-tumors will be reduced even by doses ineffective as monotherapy. The MTDQ pretreatment of NKLy ascites tumorbearing rats raised survival rat by 60 to 90 per cent (controls 20%) and inhibited growth of solid Yoshida-tumors. No side-effects have been observed. In contrast to other antineoplastic agents MTDQ does not induce granulocytopenia.
D000818:Animals; D000970:Antineoplastic Agents; D000975:Antioxidants / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D005260:Female; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D011804:Quinolines / Q000494:pharmacology*; D011838:Radiation-Sensitizing Agents; D012517:Sarcoma, Yoshida / Q000188:drug therapy
D000970:Antineoplastic Agents; D000975:Antioxidants; D011804:Quinolines; D011838:Radiation-Sensitizing Agents; C011923:6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline)
Untersuchung der radiosensibilisierenden und tumorhemmenden Wirkung des als MTDQ (6,6' methylen bis/2,2,4-trimethyl-1,2-dihydroquinolin) bezeichneten antioxidans